Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash & Equivalents (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Cash & Equivalents for 13 consecutive years, with $118.1 million as the latest value for Q1 2026.

  • For Q1 2026, Cash & Equivalents rose 211.32% year-over-year to $118.1 million; the TTM value through Mar 2026 reached $118.1 million, up 211.32%, while the annual FY2025 figure was $165.8 million, 521.57% up from the prior year.
  • Cash & Equivalents hit $118.1 million in Q1 2026 for Viking Therapeutics, down from $165.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $195.6 million in Q1 2024 and bottomed at $18.4 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $79.4 million, with a median of $50.3 million recorded in 2024.
  • Year-over-year, Cash & Equivalents surged 1629.43% in 2022 and then crashed 89.72% in 2023.
  • Viking Therapeutics' Cash & Equivalents stood at $36.6 million in 2022, then soared by 51.55% to $55.5 million in 2023, then crashed by 51.95% to $26.7 million in 2024, then skyrocketed by 521.57% to $165.8 million in 2025, then dropped by 28.76% to $118.1 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $118.1 million, $165.8 million, and $100.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.